Compile Data Set for Download or QSAR
Report error Found 305 Enz. Inhib. hit(s) with all data for entry = 11751
TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644590(US11866450, Compound 3 | US11866450, Compound 2)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644592(US11866450, Compound 4 | Preparation of 7,7-dimeth...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644593(US11866450, Compound 6 | US11866450, Compound 5)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644593(US11866450, Compound 6 | US11866450, Compound 5)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644589(US11866450, Compound 1 | Preparation of 11-[3-(2,2...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644599(US11866450, Compound 11 | Preparation of (15S)-12,...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644600(US11866450, Compound 12 | Preparation of 12,12-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644602(US11866450, Compound 14 | Preparation of (14R)-12,...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644595(US11866450, Compound 8 | US11866450, Compound 7)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644597(US11866450, Compound 9 | Preparation of 12,12,19-t...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644623(US11866450, Compound 36 | US11866450, Compound 35)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644623(US11866450, Compound 36 | US11866450, Compound 35)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644625(US11866450, Compound 37 | Preparation of 12,12-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644620(US11866450, Compound 32 | Preparation of 20,20-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644622(US11866450, Compound 34 | Preparation of (15S)-12,...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644631(US11866450, Compound 43 | Preparation of 8-[3-(3,3...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644632(US11866450, Compound 45 | US11866450, Compound 44)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644628(US11866450, Compound 40)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644630(US11866450, Compound 42 | Preparation of 12,12-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644608(US11866450, Compound 20 | Preparation of 7,7-dimet...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644609(US11866450, Compound 22 | US11866450, Compound 21)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644603(US11866450, Compound 15 | Preparation of 12,12-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644604(US11866450, Compound 16 | Preparation of 12,12-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644606(US11866450, Compound 18)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644614(US11866450, Compound 27 | US11866450, Compound 26)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644616(US11866450, Compound 28 | Preparation of 12,12-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644617(US11866450, Compound 30 | US11866450, Compound 29)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644617(US11866450, Compound 30 | US11866450, Compound 29)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644612(US11866450, Compound 25 | US11866450, Compound 24)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644614(US11866450, Compound 27 | US11866450, Compound 26)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644655(US11866450, Compound 68 | US11866450, Compound 67)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644655(US11866450, Compound 68 | US11866450, Compound 67)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644657(Preparation of 12,12-dimethyl-8-(3-{2-[1-(trifluor...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644658(US11866450, Compound 70)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644651(US11866450, Compound 64 | US11866450, Compound 63)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644651(US11866450, Compound 64 | US11866450, Compound 63)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644653(Preparation of (14R)-8-[3-(3,3-dicyclopropylpropox...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644654(Preparation of (14S)-8-[3-(3,3-dicyclopropylpropox...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644662(US11866450, Compound 75 | US11866450, Compound 74)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644664(Preparation of (14S)-12,12-dimethyl-8-(3-{2-[1-(tr...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644665(Preparation of 12,12-dimethyl-8-(3-{2-[1-(trifluor...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644666(Preparation of (14S)-8-[3-(3,3-dimethylbutyl)-2-ox...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644660(US11866450, Compound 73 | US11866450, Compound 72)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644640(US11866450, Compound 52)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644641(US11866450, Compound 53 | Preparation of 12,12-dim...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644634(US11866450, Compound 47 | US11866450, Compound 46)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644636(US11866450, Compound 49 | US11866450, Compound 48)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644646(US11866450, Compound 59 | US11866450, Compound 60 ...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644646(US11866450, Compound 59 | US11866450, Compound 60 ...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM644646(US11866450, Compound 59 | US11866450, Compound 60 ...)
Affinity DataEC50: <1.00E+3nMAssay Description:Bath 1 Buffer consisted of 1 mM MgCl2, 160 mM NaCl, 4.5 mM KCl, 10 mM HEPES, 10 mM Glucose, 2 mM CaCl2).Chloride Free Buffer consisted of 1 mM Magnes...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

Displayed 1 to 50 (of 305 total ) | Next | Last >>
Jump to: